These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32566961)

  • 1. Efavirenz as a potential drug for the treatment of triple-negative breast cancers.
    Chiou PT; Ohms S; Board PG; Dahlstrom JE; Rangasamy D; Casarotto MG
    Clin Transl Oncol; 2021 Feb; 23(2):353-363. PubMed ID: 32566961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells.
    Patnala R; Lee SH; Dahlstrom JE; Ohms S; Chen L; Dheen ST; Rangasamy D
    Breast Cancer Res Treat; 2014 Jan; 143(2):239-53. PubMed ID: 24337508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
    Hecht M; Erber S; Harrer T; Klinker H; Roth T; Parsch H; Fiebig N; Fietkau R; Distel LV
    PLoS One; 2015; 10(6):e0130277. PubMed ID: 26086472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China.
    Chen R; Chen J; Xun J; Hu Z; Huang Q; Zhang R; Steinhart C; Shen Y; Liu L; Lu H
    Pharmacogenomics; 2020 Aug; 21(13):945-956. PubMed ID: 32838647
    [No Abstract]   [Full Text] [Related]  

  • 5. LINE-1 as a therapeutic target for castration-resistant prostate cancer.
    Houede N; Piazza PV; Pourquier P
    Front Biosci (Landmark Ed); 2018 Jan; 23(7):1292-1309. PubMed ID: 28930600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.
    El Hadri K; Glorian M; Monsempes C; Dieudonné MN; Pecquery R; Giudicelli Y; Andreani M; Dugail I; Fève B
    J Biol Chem; 2004 Apr; 279(15):15130-41. PubMed ID: 14722061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
    Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Pediatric Orodispersible Tablets Based on Efavirenz as a New Therapeutic Alternative.
    de Freitas Neto JL; do Nascimento Gomes Barbosa I; de Melo CG; Ângelos MA; Dos Santos Mendes LM; Ferreira MRA; Rolim LA; Soares LAL; da Silva RMF; Neto PJR
    Curr HIV Res; 2020; 18(5):342-353. PubMed ID: 32614748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
    Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
    Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
    Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
    Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid binding protein 7 mediates linoleic acid-induced cell death in triple negative breast cancer cells by modulating 13-HODE.
    Kwong SC; Abd Jamil AH; Rhodes A; Taib NA; Chung I
    Biochimie; 2020 Dec; 179():23-31. PubMed ID: 32931863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.